亿帆医药：子公司维生素K1注射液获得药品注册证书

Core Viewpoint - The company announced that its wholly-owned subsidiary, Hefei Yifan Biopharmaceutical Co., Ltd., received the drug registration certificate for Vitamin K1 injection from the National Medical Products Administration on January 5, 2026, indicating a significant milestone in its product development [1] Group 1 - The Vitamin K1 injection is intended for the prevention and treatment of vitamin K deficiency bleeding in infants [1] - The company has invested approximately 20.66 million yuan in the research and development of the Vitamin K1 injection as of the date of the report [1]